Acquired drug resistance is a major cause of high lethality in pancreatic cancer. Gemcitabine resistance is the most common in the clinic. Exploring the specific molecular mechanism of gemcitabine resistance in pancreatic cancer will facilitate using gemcitabine rationally in the clinic and improve the quality of life and survival of patients. Long non-coding RNAs (lncRNAs) play an important role in gemcitabine resistance of pancreatic cancer. Because of specific expression after drug resistance in tumors, lncRNAs have become ideal targets to restore gemcitabine sensitivity in pancreatic cancer. In this review, we summarize the specific mechanisms of various lncRNAs in gemcitabine resistance of pancreatic cancer to explore possible therapeutic targets related to lncRNA to alleviate gemcitabine resistance of pancreatic cancer.